

Seminars in Hematology

TABLE OF CONTENTS

Volume 53 ■ Issue 2 ■ Suppl 1 ■ April 2016

**5TH INTERCONTINENTAL COOPERATIVE ITP STUDY GROUP (ICIS)
EXPERT MEETING IN FLÜELI-RANFT, SWITZERLAND, SEPTEMBER 2015**
Thomas Kühne, MD, and Paul Imbach, MD, Guest Editors

- S1** 5th Intercontinental Cooperative ITP Study Group (ICIS) expert meeting in Flüeli-Ranft, Switzerland, September 2015
Paul Imbach and Thomas Kühne
- S2** The nonhemostatic immune functions of platelets
Rick Kapur and John W. Semple
- S7** From immune substitution to immunomodulation
Volker Wahn
- S10** Immunomodulation of immunothrombocytopenia
Falk Nimmerjahn
- S13** T cells in the pathogenesis of immune thrombocytopenia
Yu Wei and Ming Hou
- S16** Imbalanced immune homeostasis in immune thrombocytopenia
Karina Yazdanbakhsh
- S20** Mechanistic properties of intravenous immunoglobulin in murine immune thrombocytopenia: support for Fc γ RIIB falls by the wayside
Andrew R. Crow and Alan H. Lazarus
- S23** Immune modulation for autoimmune disorders: evolution of therapeutics
Howard A. Liebman
- S27** What do we learn from immunomodulation in patients with immune thrombocytopenia?
Masataka Kuwana
- S31** Thrombopoietin receptor agonists: a new immune modulatory strategy in immune thrombocytopenia?
Alexandra Schifferli and Thomas Kühne
- S35** Refractory autoimmune disease: an overview of when first-line therapy is not enough
Cindy Neunert, Roula Farah, Joanne Yacobovich and Ellis Neufeld

- S39** Immunomodulation and immune thrombocytopenia: some unmet needs, questions, and outlook
Bertrand Godeau
- S43** Management of chronic immune thrombocytopenia in children and adolescents: lessons from an Austrian national cross-sectional study of 81 patients
J. Sipurzynski, B. Fahrner, R. Kerbl, R. Crazzolara, N. Jones, G. Ebetsberger, B. Jauk, V. Strenger, B. Wohlmuther, W. Schwinger, H. Lackner, C. Urban, W. Holter, M. Minkov, L. Kager, M. Benesch, and M.G. Seidel
- S48** Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine
Mojca Bizjak, Or Bruck, Darja Kanduc, Sonja Praprotnik, and Yehuda Shoenfeld
- S51** Current treatments and developments in pemphigoid diseases as paradigm diseases for autoantibody-driven, organ-specific autoimmune diseases
Christian D. Sadik and Detlef Zillikens
- S54** Immunological treatment of multiple sclerosis
Martin Diebold and Tobias Derfuss
- S58** Immunomodulation of rheumatologic disorders with non-biologic disease modifying antirheumatic drugs
Ulrich A. Walker
- S61** Celiac disease with Evans syndrome and isolated immune thrombocytopenia in monozygotic twins: a rare association
Jelena Roganovic
- S64** Anti-D treatment for pediatric immune thrombocytopenia: Is the bad reputation justified?
Joanne Yacobovich, Sabreen Abu-Ahmed, Orna Steinberg-Shemer, Tracie Goldberg, Miriam Cohen, and Hannah Tamary
- S67** Serum vitamin D levels in children with newly diagnosed and chronic immune thrombocytopenia
Srđana Čulić, Joško Markić, Davor Petrović, Paško Konjevoda, and Jasminka Pavelić
- S70** Viruses, anti-viral therapy and viral vaccines in children with immune thrombocytopenia
Mohsen S. Elalfy and Diane Nugent

Seminars in Hematology

**5TH INTERCONTINENTAL COOPERATIVE ITP STUDY GROUP (ICIS)
EXPERT MEETING IN FLÜELI-RANFT, SWITZERLAND, SEPTEMBER 2015
Thomas Kühne, MD, and Paul Imbach, MD, Guest Editors**

This supplement was sponsored by the Intercontinental Cooperative ITP Study Group, Amgen, Baxalta/Baxter, Biotest, CSL-Behring, Novartis, Novo-Nordisk, and Octapharma

Dosages, indications and methods of use for compounds that are referred to in the supplement by authors may reflect their clinical experience or may be derived from professional literature or other clinical sources. Because of differences between in vitro and in vivo systems and between laboratory animals models and clinical data in humans, in vitro and animal data may not correlate with clinical results and do not demonstrate clinical safety or efficacy in humans.

